|
2016, Volume 32, Number 3, Page(s) 178-185
|
|
DOI: 10.5146/tjpath.2015.01354 |
Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases |
Mohamed Mokhtar DESOUKI1, Ihab Shafek ATTA2, Daynna J WOLFF3, Sally E SELF3 |
1Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, NASHVILLE, TN, UNITED STATES 2Department of Pathology, Al Azhar University, Faculty of Medicine, Assuit Branch, EGYPT 3Medical University of SC, CHARLESTON, SC, UNITED STATES |
Keywords:
Estrogen receptor, Progesterone receptor, HER2, Breast cancer, Lymph node metastasis |
Objective: In the current work, we compared HER2 by fluorescence in situ hybridization and estrogen and progesterone receptors by
immunohistochemistry in matched primary breast carcinomas and their lymph node metastases.
Material and Method: Thirty-nine cases of primary and lymph node metastases were assessed for HER2. Primary tumors of the cases selected
were known to be HER2 negative. Also, immunohistochemistry for estrogen and progesterone receptors was performed on 36 cases from the
same cohort to assess any discrepancy between the primary tumor and the lymph node metastases.
Results: Out of 39 cases, one case was HER2 amplified in lymph node metastasis compared to non-amplified primary tumor. Approximately
eight percent of cases (3/36) were estrogen receptor-negative in LN metastasis and 5.55% (2/36) were less strongly positive compared to the
positive primary tumors. Nineteen percent (7/36) were progesterone receptor-negative in lymph node metastasis in contrast to the matched
positive primary tumors, and 5.55% (2/36) were progesterone receptor-positive in lymph node as compared to their corresponding negative
primary tumors.
Conclusion: While most matched primary breast tumors and lymph node metastases show concordance in HER2, estrogen and progesterone
receptor status, we confirmed the multiple reports that identified discordant results in a subset of cases. These results support the newly adopted
guidelines that require testing for HER2 on metastatic lesions.
|
|
|
|